PEDRO
PÉREZ SEGURA
Profesor asociado de Ciencias de la Salud
![Foto de PEDRO](/img/nophoto.png)
![Foto de Hospital del Mar](/img/noimage_org.png)
Hospital del Mar
Barcelona, EspañaPublications en collaboration avec des chercheurs de Hospital del Mar (13)
2024
-
A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma
Journal of Neuro-Oncology, Vol. 166, Núm. 3, pp. 407-415
-
Correction to: A combined analysis of two prospective randomised studies exploring the impact of extended post-radiation temozolomide on survival outcomes in newly diagnosed glioblastoma (Journal of Neuro-Oncology, (2024), 166, 3, (407-415), 10.1007/s11060-023-04513-1)
Journal of Neuro-Oncology
2021
-
SEOM clinical guideline for management of adult medulloblastoma (2020)
Clinical and Translational Oncology, Vol. 23, Núm. 5, pp. 940-947
2020
-
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
Neuro-oncology, Vol. 22, Núm. 12, pp. 1851-1861
2018
-
Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients
Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1529-1537
2017
-
Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 682-694
-
Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification
Neuro-Oncology, Vol. 19, Núm. 11, pp. 1522-1531
2016
-
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial
Journal of Neuro-Oncology, Vol. 127, Núm. 3, pp. 569-579
2015
-
A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma
Clinical and Translational Oncology, Vol. 17, Núm. 9, pp. 743-750
-
Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 17, Núm. 10, pp. 763-771
2012
-
Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO)
Anti-Cancer Drugs, Vol. 23, Núm. 6, pp. 659-665
-
Role of flow cytometry immunophenotyping in the diagnosis of leptomeningeal carcinomatosis
Neuro-Oncology, Vol. 14, Núm. 1, pp. 43-52
2009
-
Prevención del cáncer colorrectal
Gastroenterologia y Hepatologia